Antibody level after hepatitis-B vaccination in hemodialysis patients: Impact of dialysis adequacy, chronic inflammation, local endemicity and nutritional status

Journal of the National Medical Association

Volumn 98, Issue 12, 2006, Pages 1953-1957

  Ibrahim, Salwa ^a,b   El Din, Sharaf ^a,b   Bazzal, Ibrahim ^a,b  

^a Cairo University ^*  (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Chronic inflammation; Hemodialysis; Hepatitis B; Nutritional state; Vaccination

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; SERUM ALBUMIN; TRANSFERRIN; UREA;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY MASS; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CORRELATIONAL STUDY; ENDEMIC DISEASE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEPATITIS B; HUMAN; MALE; MOLECULAR EVOLUTION; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION;

ADULT; CHRONIC DISEASE; EGYPT; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; VACCINATION;

EID: 33845659507     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cheng CH, Huang CC, Leu ML, et al. Hepatitis B vaccine in hemodialysis patients with hepatitis C infection. Vaccine. 1997;15(12-13):1353-1357.
2. CDC. Outbreaks of Hepatitis B Virus infection Among Hemodialysis Patients-California, Nebraska, and Texas, 1994. MMWR. 1996;45:285-288.
3. Qirbi N, Hall AJ. Epidemiology of hepatitis B virus infection in the Middle East. East Wediterr Health J. 2001;7:1034-1045.
4. Navarro JF, Teruel JL, Mateos ML, et al. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16(2):95-97.
5. Buti M, Viladomiu L, Jardi R, et al. Long term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol. 1992;12 (3):144-147.
6. Pasko MT, Bartholomew WR, Beam TR, et al. Long term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. Am J Kidney Dis. 1988;11(4):326-331.
7. Docci D, Cipolloni P, Baldrati L, et al. Immune response to a recombinant hepatitis B vaccine in hemodialysis patients. Inf J Artif Organs. 1990;13 (7):451-453.
8. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts Seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42(6):1184-1192.
9. Magnani G, Calzetti C, Campari M, et al. Immune response to hepatitis B vaccine and duration of protection in a dialysis unit. Acta Siomed Ateneo Parmense. 1987;58(1-2):41-47.
10. Fernandez E, Betriu MA, Gomez R, et al. Response to the hepatitis B virus vaccine in hemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephral Dial Transplan. 1996;11:1559-1563.
11. Dacko C, Holley J. The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients. Adv Perif Dial. 1996;12:315-317.
12. Eardley K, Jones H, Osman H, et al. Efficacy of the accelerated hepatitis B vaccination schedule used in hemodialysis patients post-exposure to virus: a single centre experience. Nephrol Dial Transplant. 2002;17:1982-1987.
13. Tele SA, Martins RM, Lopes CL, et al. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients and staff. Eur J Epidemiol. 2001;17:145-149.
14. Daugirdas JT. Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther. 1995;2:295-304.
15. Daugirdas JT, Van Stone JC. Physiologic principles and urea kinetics modelling. In: Handbook of Dialysis, 3rd ed. Daugirdas JT, Blake P, Ing T, eds. Lippincott Williams & Wilkins, 2001:15-45.
16. Goldestein D. Assessment of nutritional status in renal diseases. In: Handbook of nutrition and the kidney, 3rd ed. Mitch W, Klahr S, eds. Lippincott-Raven; 1998:45-86.
17. National Kidney Foundation. K/DOQI Update 2000. www.kidney.org/ professional/kdoqi/guidelines.
18. Chetanoud L, Herbelin A, Beauran G, et al. Immune deficiency of uremic patients. Adv Nephrol. 1990;19:259-274.
19. Peces R, de la Torre M, Alcazar R, et al. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis. 1997;29(2):239-245.
20. Roozbeh J, Moini M, Lankarani KB, et al. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysiS: ASAIO J. 2005;51(3):242-245.
21. Kara I, Yilmaz M, Suner A, et al. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine 22:3963-3967, 2004.
22. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end stage renal disease. Aliment Pharmacol Ther. 2004;20:1053-1062.
23. Elwell RJ, Neumann M, Bailie GR. Factors associated with long term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort study. Pharmacotherapy. 2003;23 (12):1558-1563.
24. Vlassopoulos D. Hepatitis B vaccination in chronic renal failure patients. www.uninet.ed/cin2003/conf/index.html.
25. Girndt M, Kohler H, Schiedhelm-Weick E, et al. Production of interleukin-6, tumor necrosis factor- and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 1995; 47:559-565.
26. Girndt M, Sester U, Sester M, et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int. 2001;60(6):2385-2391.
27. Kovacic V, Sain M, Vukman V. Does efficient hemodialysis improve the response to hepatitis B virus vaccination? Lijec Vjesn. 2004;126(5-6):133-137.
28. Girndt M, Sester M, Sester U, et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int. 2001;59:1382-1389.
29. Weinstein T, Chagnac A, Boaz M, et al. Improved immnogenicity of a novel third generation recombinant hepatitis B vaccine in patients with end stage renal disease. Nephron Clin Pract. 2004;97:c67-c72.
30. Afifi A, Karim MA. Renal replacement therapy in Egypt: first annual report of the Egyptian society of nephrology. East Mediterr Health J. 1999;5(5):1023-1029.
31. Cheng CH, Huang CC, Leu ML, et al. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. Vaccine. 1997;15(12-13):1353-1357.
32. Majdan M, Polz M, Ksiazek A, et al. The response to the hepatitis B virus vaccine in patients undergoing hemodialysis and peritoneal dialysis-personal experience. Przegl Lek. 1995:52(6):307-310.
33. Muszytowski M, Manitius J, Ruszkiewicz-Folda M. Prevalence of response to anti-HBV infection in patients on maintenance hemodialysis infected with hepatitis C virus (HCV). Przegl Lek. 1996;53(5):417-419.